You are here

  • Home
  • Archive
  • Volume 32, Issue 7
  • Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

Article Text

Article menu
Download PDFPDF
Clinical trial
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)
  1. Gabriella Macchia1,
  2. Barbara Alicja Jereczek-Fossa2,3,
  3. Roberta Lazzari2,
  4. Annamaria Cerrotta4,
  5. Francesco Deodato1,5,
  6. Edy Ippolito6,
  7. Cynthia Aristei7,
  8. Maria Antonietta Gambacorta5,8,
  9. Giovanni Scambia9,10,
  10. Vincenzo Valentini5,8 and
  11. Gabriella Ferrandina9,10
  1. 1 Radiotherapy Unit, Gemelli Molise Hospital, Campobasso, Italy
  2. 2 Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milano, Italy
  3. 3 Department of Oncology and Hemato-oncology, University of Milan, Milano, Italy
  4. 4 Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
  5. 5 Istituto di Radiologia, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy
  6. 6 Department of Radiation Oncology, Campus Bio-Medico University, Roma, Italy
  7. 7 Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy
  8. 8 Unità Operativa Complessa di Radioterapia, Dipartimento di Scienze Radiologiche, Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
  9. 9 Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
  10. 10 Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy
  1. Correspondence to Dr Gabriella Macchia, Radiotherapy Unit, Gemelli Molise, Campobasso, Molise, Italy; macchiagabriella{at}gmail.com

Abstract

Background Stereotactic body radiotherapy (SBRT) has shown promising results in the clinical setting of oligometastatic, persistent, or recurrent disease in several malignancies including ovarian cancer.

Primary Objective The MITO-RT3/RAD trial is a prospective, multicenter phase II study aimed at identifying potential predictors of response and clinical outcome after SBRT treatment.

Study Hypothesis Radiotherapy delivered by pre-defined SBRT treatment schedules and shared constraints could improve the rate of complete response.

Trial Design All patients accrued will be treated with a radiotherapy dose in the range of 30–50 Gy by 1, 3, or 5 SBRT daily fractions to all sites of active metastatic disease according to diagnostic imaging. Schedules of treatment and dose prescription have been established before considering target sites and healthy organ dose constraints. Follow-up and monitoring of side effects will be carried out every 3 months for the first year with imaging and clinical evalutation, and every 4 months within the second year; thereafter, surveillance will be carried out every 6 months. The best response on a per lesion basis will be evaluated by computed tomographic (CT) scan, positron emission tomography/CT, or magnetic resonance imaging in case of brain lesions, every 3 months.

Major Inclusion/Exclusion Criteria The study includes patients with oligometastatic, persistent, or recurrent ovarian cancer for which salvage surgery or other local therapies are not feasible due to any relative contra-indication to further systemic therapy because of serious co-morbidities, previous severe toxicity, unavailability of potentially active systemic therapy, or patient refusal.

Primary Endpoint The primary endpoint of the study is the clinical complete response rate to SBRT by imaging on a per lesion basis.

Sample Size Approximately 205 lesions will be treated (90 lymph nodes and 115 parenchyma lesions).

Estimated Dates for Completing Accrual and Presenting Results Fifty-two centers have expressed their intention to participate. Enrollment should be completed by March 2023 and analysis will be completed in September 2023.

Trial Registration NCT04593381.

  • ovarian cancer
  • radiation oncology
  • radiotherapy dosage

Data availability statement

Data may be obtained from a third party and are not publicly available.

https://doi.org/10.1136/ijgc-2021-002709

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    Data may be obtained from a third party and are not publicly available.

    View Full Text

    Footnotes

    • Collaborators Luca Boldrini; Maura Campitelli; Alessia Nardangeli; Mauro Manna.

    • Contributors Conception and design: GM, GF. Revision of study design and protocol: GF, GM, BAJF, CA, AC, MAG. Study coordination: GM, GF, FD, MAG. Acquisition of data and patient recruitment: GF, GM, BAJF, RL, CA, AC, FD, EI, GS, MAG, VV. Radiotherapy quality check (of protocol): GM, BAJF, CA, FD, EI. Data management and statistical analysis: GF, GM. Revision, adaptation, and final approval of manuscript: All authors. Accountable for all aspects of the work: All authors.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.